Tissue-Type Plasminogen Activator and Its Inhibitor Plasminogen

0013-7227/04/$15.00/0 Printed in U.S.A.

Endocrinology 145(4):1767–1775 Copyright © 2004 by The Endocrine Society doi: 10.1210/en.2003-1327

Tissue-Type Plasminogen Activator and Its Inhibitor Plasminogen Activator Inhibitor Type 1 Are Coordinately Expressed during Ovulation in the Rhesus Monkey YI-XUN LIU, KUI LIU, QIANG FENG, ZHAO-YUAN HU, HAI-ZHEN LIU, GUO-QING FU, YIN-CHUAN LI, RU-JIN ZOU, AND TOR NY State Key Laboratory of Reproductive Biology (Y.-X.L., Q.F., Z.-Y.H., H.-Z.L., G.-Q.F., Y.-C.L., R.-J.Z.), Institute of Zoology, Chinese Academy of Sciences, Beijing 100080, China; and Department of Medical Biochemistry and Biophysics (K.L, T.N.), Umeå University, SE-901 87 Umeå, Sweden Ovulation is a gonadotropin-controlled process that is essential for the propagation of all mammalian species. In the present study, we used a pregnant mare serum gonodotropin/ human chorionic gonadotropin (hCG)-induced, synchronized ovulation model in rhesus monkeys and systematically investigated the roles of the plasminogen activator (PA) system in the ovulatory process of the primate. At different follicular developmental stages throughout the periovulatory period, samples of ovaries, granulosa cells, and theca-interstitial cells as well as follicular fluid were collected, and levels of PA and PA inhibitor type-1 (PAI-1) were evaluated by fibrin overlay, reverse fibrin overlay, Northern blot analysis, and in situ hybridization, respectively. We showed that in response to an injection of ovulation-triggering hCG, which mimics the preovulatory surge of LH in the circulation, granulosa cell-

O

VULATION, TRIGGERED BY a surge of LH released from the pituitary and recurring every reproductive cycle in female mammals, is an essential prerequisite for fertilization and subsequent embryonic development (1– 4). A mature follicle that is destined to ovulate usually protrudes markedly from the surface of the ovary, and for the ovum to escape from this structure, an extensive breakdown and remodeling of basement membranes and connective tissues that constitute the follicular wall is required (1–5). Factors leading to the occurrence of this very complex process have fascinated biologists for many years. Several lines of evidence have suggested that plasmin-mediated proteolysis plays a role in the breakdown of the follicle wall during ovulation in rodents (for reviews, see Refs. 1, 4, 6 –9). The plasminogen activator (PA) system is a versatile, temporally controlled enzymatic system that comprises plasminogen, which is activated to the proteolytic enzyme plasmin by either of the two physiological PAs, tissue-type PA

Abbreviations: FF, Follicular fluid; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GC, granulosa cell; hCG, human chorionic gonadotropin; PA, plasminogen activator; PAI, PA inhibitor; PMSG, pregnant mare serum gonodotropin; SDS, sodium dodecyl sulfate; SSC, NaCl and Na citrate; TIC, theca-interstitial cell; tPA, tissue-type PA; uPA, urokinase-type PA. Endocrinology is published monthly by The Endocrine Society (http:// www.endo-society.org), the foremost professional society serving the endocrine community.

derived tissue-type PA (tPA) was substantially elevated in preovulatory follicles and reached its maximum level just before ovulation. Although theca-interstitial cell-derived PAI-1 was also stimulated by pregnant mare serum gonodotropin and hCG treatments, however, the maximum level of PAI-1 appeared 12 h earlier than that of tPA. When ovulation approached, accompanying the highest tPA level in the preovulatory follicles, the follicular PAI-1 level declined dramatically to its minimum value. Moreover, our data on the expression of follicular PA and PAI-1 over the periovulatory period were reinforced by results obtained at the mRNA level. Our data suggest that the coordinated expression of tPA and PAI-1 may be of importance for the follicular rupture process during ovulation in the primate. (Endocrinology 145: 1767–1775, 2004)

(tPA) and urokinase-type PA (uPA). Activation of this system is initiated by release of tPA or uPA by specific cells in response to external signals such as hormones, growth factors, or cytokines that lead to locally expressed extracellular proteolytic activities (1, 4, 9, 10). The PA system is also regulated by specific inhibitors directed against PAs and plasmin, including PA inhibitor (PAI) type-1, PAI-2, protease nexin 1, and ␣2-antiplasmin (4, 9, 11). Many studies have suggested that the PA system plays a crucial role in the degradation of the follicular wall during ovulation in rodents. In rats, ovulation is preceded by a transient and cellspecific expression of tPA and PAI-1, which causes a proteolytic activity localized to the surface of the ovary just before ovulation (for reviews, see Refs. 1, 4, 8, 9). Studies with intrabursal injections of ␣2-antiplasmin or antibodies against tPA partially block gonadotropin-induced ovulation in rats (12). Our previous results with gene-deficient mice have demonstrated that tPA and uPA double-knockout mice have a 26% decreased ovulation rate (13). However, plasminogen knockout mice showed a normal ovulation rate, indicating that plasmin is not required for efficient follicular rupture or for activation of other proteases involved in the mouse ovulatory process. Alternatively, the role of plasmin may be effectively compensated for by other mechanisms in the absence of plasmin in the mouse ovary (14). Thus, the role of the PA system in ovulation is still not fully

1767

1768

Endocrinology, April 2004, 145(4):1767–1775

understood. Little is known about whether the PA system participates in the ovulation process in the primate. Answering this question has been somewhat hindered by limited availability of primate ovarian materials that represent the entire periovulatory process. In this study, we used a gonadotropin-induced, synchronized ovulation model in rhesus monkeys and collected ovarian samples at different follicular developmental stages throughout the periovulatory process. The expression and functions of tPA, uPA, and their physiological inhibitor PAI-1 were investigated in follicles during the ovulatory process. Materials and Methods Rhesus monkeys (Macaca mulatta) Fifteen prepubertal (2–2.5 yr old) and 13 adult (5–7 yr old) female rhesus monkeys were obtained from the Primate Research Center of Kunming Institute of Zoology, Chinese Academy of Sciences (Kunming, China). The use of monkeys for this study was approved by the Academic Committee of the Institute of Zoology, Chinese Academy of Sciences, and a World Health Organization Review Committee. As experimental animals, rhesus monkeys have long pregnancy periods and low birth rates, and their availability can be limited from time to time. Thus, in this study both adult and prepubertal monkeys were used. Our previous studies (15–17) have shown that follicles from both prepubertal and adult monkeys can grow and ovulate upon gonodotropin stimulation. The only difference is that adult monkeys have fewer, and comparatively smaller, developing follicles (4 –10 follicles of 3– 8 mm in diameter per ovary), compared with those of prepubertal monkeys (15–20 follicles of 5– 8 mm in diameter per ovary). Ovaries from prepubertal monkeys can therefore generate more granulosa cells (GCs) and theca-interstitial cells (TICs). Also as a result of their availability, we used prepubertal monkeys for the protein level analyses shown in Figs. 1–5 and adult monkeys for mRNA level analyses in Figs. 6 and 7. When adult female monkeys were used, they were treated with gonadotropins only during the reproductive season (from October to February in Kunming, China) when their ovaries were capable of responding to exogenous hormone treatment To induce ovulation, animals were treated with a pregnant mare serum gonodotropin (PMSG)/human chorionic gonadotropin (hCG) based on a regimen developed by the Wisconsin Regional Primate Research Center (15–18). After an initial im injection of 950 IU PMSG on d 1 (which was any day for the prepubertal monkeys and the second day of menstrual bleeding for the adult monkeys), 300 IU PMSG was administered on d 2, 4, and 6, followed by daily injections of 300 IU PMSG on d 8 –12. On d 13, a single im injection of 4000 IU hCG was administered. At various time points after hormone treatment, follicular sizes were monitored during surgery when they were collected for experiments. Typically, follicles before PMSG treatment were very small with diameters less than 0.8 mm in both prepubertal and adult monkeys. After the 12 d of treatment with PMSG, developing follicles normally reached 5– 8 mm in diameter in prepubertal monkeys and 3– 8 mm in adult monkeys. Further treatment with hCG did not alter the follicular sizes significantly. Typically, at a time point of 36 h after hCG injection, we observed large preovulatory follicles full of follicular fluid protruding from ovaries, which were very close to the start of ovulation. Also, we observed newly formed corpora lutea full of blood 48 –72 h after hCG injection. Thus, it was fairly obvious that ovulation in our gonadotropininduced monkeys took place 36 – 48 h after hCG treatment. After 12 d of PMSG injection (representing the stage of developed follicles) and 12, 24, and 36 h of hCG injection (representing the preovulatory stage), the animals were maintained under ketamine hydrochloride-induced anesthesia, and the ovaries were removed by abdominal surgery in a standard operation room.

Reagents and hormones McCoy’s 5A medium (modified, without serum), penicillin, streptomycin, l-glutamine, HEPES, trypan blue, plasminogen, and thrombin were obtained from Sigma Chemical Co. (St. Louis, MO). Acrylamide,

Liu et al. • PA System in Monkey Ovulation

N,N-methylenebisacrylamide, sodium dodecyl sulfate (SDS), TEMED, ammonium persulfate, and Coomassie brilliant blue were purchased from Bio-Rad Laboratories (Richmond, CA). PMSG was obtained from Changchun Institute of Biological Products (Changchun, China), and hCG was obtained from the State Key Laboratory of Dr. Yushu Xu (Institute of Zoology, Chinese Academy of Sciences, Beijing, China). Purified human tPA, uPA, goat antihuman tPA, and goat antihuman PAI-1 antibodies were obtained from Biopool (Umeå, Sweden). Goat polyclonal anti-uPA antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Fibrinogen was obtained from Calbiochem (La Jolla, CA).

Preparation of GCs, TICs and follicular fluid Monkey ovaries at different stages were dissected by surgery and rinsed in McCoy’s 5A medium containing penicillin and streptomycin. For preparation of GCs, developed or preovulatory follicles were punctured with 25-gauge hypodermic needles, and the released cells were collected by centrifugation. After removing GCs, the residual ovaries were washed thoroughly in McCoy’s 5A medium to remove free cells, transferred into McCoy’s 5A medium containing 0.08% collagenase, and incubated at 37 C for 10 min. The dissociated GCs were discarded and the residual ovarian fragments were further incubated in McCoy’s 5A medium containing 0.4% collagenase at 37 C for approximately 1 h to yield TICs. The cells were washed twice with culture medium, and viability was determined by trypan blue exclusion. As revealed by microscopy, the GC and TI cell preparations were essentially pure, especially the GCs. To determine the purity of the prepared GCs and TICs more accurately, we cultured the cells in the presence of androgen, which is a substrate for estrogen synthesis by GCs. Because TICs do not express aromatase, they cannot synthesize estrogen from androgen. This is in contrast to GCs, which express aromatase and can therefore convert androgen to estrogen (19). Judging from the estrogen production by the cultured GC and TIC preparations, we estimated that the isolated TICs contain less than 5% GC contamination. Aliquots of each preparation of GCs or TICs containing 5 ⫻ 105 cells or 5 ⫻ 106 cells were frozen at ⫺80 C for further analysis of PA and PAI-1 activities or mRNA content, respectively. Follicular fluid (FF) was also collected from preovulatory follicles 12, 24, and 36 h after hCG treatment.

Cell cultures GCs and TICs (5 ⫻ 105 cells/well) were seeded in 24-well culture plates (Corning Glass Works, Corning, NY) containing 0.5 ml/well of serum-free McCoy’s 5A medium supplemented with l-glutamine (2 mm), penicillin (100 U/ml), and streptomycin sulfate (100 ␮g/ml). The cells were cultured in 95% air and 5% CO2 at 37 C. After 24 h of incubation, the conditioned media were harvested, centrifuged, and stored at ⫺20 C for measurement of tPA and PAI-1 activities.

SDS-PAGE PA and PAI-1 antigens in cell culture medium and cell lysates were fractionated by SDS-PAGE. Electrophoresis was performed at 50 V overnight until the dye front reached the bottom of the gel. After electrophoresis, the gel was washed for 2 ⫻ 45 min in 2.5% (vol/vol) Triton X-100 solution to remove SDS in the gel and rinsed once with distilled water before being applied to the surface of a fibrin/agar indicator gel.

Fibrin overlay and reversed fibrin overlay assays The fibrin-agar indicator gel for PA activity assay was prepared based on a method developed by Granelli-Piperno and Reich (20), with modifications. The fibrin-agar gel contained plasminogen (25 mg/ml), fibrinogen (2.4 mg/ml), and thrombin (0.5 U/ml) to allow the formation of fibrin as the substrate for PA-converted plasmin. For detection of PAI-1 activity in the gel, a reversed fibrin overlay assay was used (20). In addition to plasminogen, fibrinogen, and thrombin, the reversed fibrin-agar indicator gel contained 0.05 U/ml uPA to allow autolysis of the gel. The emergence of opaque, lysis-resistant bands indicated the presence of PAI-1 activities in samples fractionated by the SDS-PAGE gel. The rinsed SDS gel was laid carefully onto the fibrin-agar gel and


incubated at 37 C in a humid chamber for about 16 h for PA activity assay and 4 –5 h for PAI-1 activity assay.

Western blot analysis of PAI-1 antigen For Western blot analysis, samples of follicular fluid or culture media were fractionated by SDS-PAGE. After electrophoresis, the proteins were transferred electrophoretically to nitrocellulose membranes and probed using a polyclonal goat antihuman PAI-1 antibody. Antibody binding was visualized using antigoat IgG antibodies conjugated with alkaline phosphatase.

Synthesis of antisense RNA probes for detection of monkey tPA and PAI-1 mRNA The riboprobes for rhesus monkey tPA and PAI-1 were prepared as previously described (16). Briefly, fragments of monkey tPA (346 bp) and PAI-1 (388 bp) cDNA were obtained by RT-PCR and subcloned into pGEM-3Z vectors. Sequencing results revealed that the monkey tPA and PAI-1 cDNA fragments had 95.78 and 96.79% identity to the corresponding human cDNA sequences, respectively. For Northern blot analysis, cDNA templates were linearized so that the antisense cRNA probes could be labeled with 32P-uridine 5-triphosphate with an in vitro transcription kit (Roche Diagnostics Corp., Indianapolis, IN). The specific activity of the probes ranged between 2 ⫻108 and 5 ⫻ 108 cpm/␮g RNA.

RNA preparation and analysis Total RNA from GCs or TICs was prepared by the Nonidet P-40 method. For hybridization analysis, total RNA was fractionated on 1% agarose gels in the presence of 2.2 m formaldehyde and transferred to nylon filters. After cross-linking under UV light, the filters were prehybridized at 62 C for 2 h in a solution containing 50% formamide, 5⫻ SSC (1⫻ SSC ⫽ 0.15 m NaCl, 0.015 m Na citrate), 8⫻ Denhardt’s solution (1.6 mg/ml Ficol, 1.6 mg/ml polyvinylpyrrolidone, and 1.6 mg/ml BSA), 0.1% SDS, 10 mm EDTA, and 25 mm yeast tRNA. The hybridization was performed in the same solution with 32P-uridine 5-triphosphate probes at 62 C overnight, followed by two to three washes in 0.1⫻ SSC containing 0.1% SDS at 65 C for about 1 h. The hybridized filters were exposed to the screen of the PhosphorImager cassette (Molecular Dynamics, Sunnyvale, CA), and data were analyzed using PhosphorImager programs (Molecular Dynamics). The relative amount of mRNA was determined by densitometric scanning of autoradiographs and normalized against levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the samples.

In situ hybridization of tPA and PAI-1 mRNAs Frozen sections (10 –12 ␮m) were prepared from adult monkey ovaries at various stages and in situ hybridization was performed as described previously (21). Slides to be used for comparison were prepared and hybridized at the same time. To monitor background levels and the specificity of the hybridization, the sense strands of the probes were included in each experiment. Photographs were taken with a camera (Carl Zeiss, New York, NY) attached to a Axioplan microscope (Zeiss) at a magnification ⫻10.

Endocrinology, April 2004, 145(4):1767–1775 1769

antihuman tPA, or antimouse uPA monoclonal antibodies. PA activities in the supernatant after immunoprecipitation were analyzed by SDS-PAGE/fibrin-overlay autography. As shown in Fig. 1, two types of PA with molecular weights equivalent to human tPA and uPA (70 and 50 kDa, respectively; data not shown) were observed in monkey ovarian lysate immunoprecipitated with normal rabbit serum. However, only uPA was detected in ovarian lysate after immunoprecipitation with anti-tPA antibody, and only tPA was seen in ovarian lysate after immunoprecipitation with antiuPA antibody. Gonadotropin regulation of tPA and uPA activities in monkey GCs during the periovulatory period

GCs obtained from follicles of prepubertal monkeys treated with PMSG/hCG were cultured for 24 h, and PA activities were analyzed in the conditioned media. As shown in Fig. 2A, conditioned medium from GCs after PMSG treatment contained a relatively low but measurable amount of tPA. Treatment with hCG dramatically increased tPA activity, which reached a high level just before ovulation (36 h after hCG injection). No uPA activity was detected in GCs before ovulation (Fig. 2A, lanes PMSG, 12–36 h after hCG injection). However, after ovulation (3 d after hCG injection), tPA activity in the luteinized GCs disappeared, whereas a dramatically increased uPA activity was observed. Although tPA and uPA are secreted proteins, we also measured the contents of tPA and uPA in GC extracts. As shown in Fig. 2B, the tPA activities measured in GC lysate were similar to those secreted into the culture media. The activity of tPA was undetectable in GC lysate after PMSG treatment, whereas it increased to high levels before ovulation (12–36 h after hCG injection). Although uPA was not detected in the conditioned medium of GC cultures before ovulation (Fig. 2A), hCG treatment stimulated the uPA content of the GC and luteal cells, and the uPA produced by luteal cells (3 d after hCG injection) was secreted into the culture medium (Fig. 2B). Gonadotropin regulation of uPA and tPA activities in monkey TICs during the periovulatory period

TICs obtained from prepubertal monkey follicles treated with PMSG/hCG were cultured for 24 h, and PA activities

Data analysis All experiments were repeated at least three times. For each time point of a single experiment, ovarian materials from one rhesus monkey were used. Representative photography using dark-field illumination for PA and PAI-1 activities as well as mean ⫾ sd of protein and mRNA levels from three experiments were shown. Data were analyzed by ANOVA. Differences among groups were calculated by Tukey’s multiple-comparison test (22), and a difference was considered to be significant with P ⬍ 0.05.

Results Identification of two types of PA (tPA and uPA) in the monkey ovary

Ovarian lysate (50 ␮g) obtained 12 h after hCG injection was immunoprecipitated with normal rabbit serum, goat

FIG. 1. Identification of tPA and uPA activities in the monkey ovary. Ovarian lysate (50 ␮g) obtained 12 h after hCG injection was immunoprecipitated with normal rabbit serum (S), goat antihuman tPA (Anti-tAb), or antimouse uPA (Anti-uAb) monoclonal antibodies. PA activities in the supernatant after immunoprecipitation were analyzed by SDS-PAGE/fibrin overlay autography. The analysis was performed with a mixture of ovarian tissues from three PMSG/hCGtreated female monkeys.

1770



FIG. 2. Gonadotropin regulation of tPA and uPA activities in monkey GCs during the periovulatory period. Prepubertal monkeys were treated with PMSG and/or hCG. The ovaries were removed at various times after gonadotropin treatment and GCs were prepared as described in Materials and Methods. GCs (5 ⫻ 105 cells/time point) were either incubated at 37 C in 0.5 ml of McCoy’s 5A medium for 24 h or directly frozen at ⫺70 C for preparation of cell lysate. The PA activities in the conditioned media (A) or the cell lysates (B) were measured by fibrin overlay technique. PMSG: 12 d after PMSG treatment; 12 h, 24 h, 36 h, 3d: time points after hCG treatment. For each time point of an experiment, cells from the ovaries of one female monkey were used. Representative photograph from three independent experiments as well as average relative levels of tPA and uPA activities (mean ⫾ SD) of three experiments were shown. Small letters (a, b, c, and d) indicate significant differences (P ⬍ 0.05).

were measured in the culture medium. As shown in Fig. 3, A and B, TICs obtained from the monkey follicles treated with only PMSG produced undetectable quantities of tPA and uPA. Only a small amount of tPA was produced by TICs just before ovulation (36 h after hCG injection). However, TIC secreted a considerable amount of uPA activity after hCG induction, at a time point just before ovulation (36 h after hCG injection). Gonadotropin regulation of PAI-1 secretion during the periovulatory period

FIG. 3. Gonadotropin regulation of uPA and tPA activities in monkey TICs during the periovulatory period. Prepubertal monkeys were treated with PMSG and/or hCG. The ovaries were removed at various times after gonadotropin treatment, and TICs were prepared as described in Materials and Methods. TICs (5 ⫻ 105 cells/time point) were incubated at 37 C in 0.5 ml McCoy’s 5A medium for 24 h, and PA activities in the conditioned media were measured by fibrin overlay technique. PMSG: 12 d after PMSG treatment; 12 h, 24 h, 36 h, 3d: time points after hCG treatment. For each time point of an experiment, cells from the ovaries of one female monkey were used. A, A representative photograph from three independent experiments; B, Average relative levels of tPA and uPA activities (mean ⫾ SD) of three experiments. Small letters (a, b, and c) indicate significant differences (P ⬍ 0.05).

To study the secretion of PAI-1 by cultured GCs and TICs, cells obtained from prepubertal monkey ovaries at various times after gonadotropin treatment were cultured for 24 h and PAI-1 protein levels were measured in the culture medium. Cultured GCs did not secrete any detectable quantity of PAI-1 (data not shown). However, as shown in Fig. 4, A and B, the PAI-1 level in the TIC conditioned medium increased in a time-dependent manner after treatment with PMSG and hCG and reached a maximum level 24 h after hCG injection. Subsequently, as ovulation approached (36 h after hCG treatment), the levels of PAI-1 were remarkably reduced. The PAI-1 level increased again after ovulation in the corpus luteum (3 d after hCG treatment). PA and PAI-1 activities in FF during the periovulatory period

PAs (tPA and uPA) and PAI-1 are secreted proteins, and PAI-1 can interact with PAs to form PA-PAI-1 complex, which neutralizes PA activities and regulates the level of free active PAs (11). To study how the coordinated expression of PAs from GCs and PAI-1 from TICs is correlated with the


ovulatory process, we collected FF samples from preovulatory follicles (12, 24, and 36 h after hCG injection) of prepubertal monkeys treated with PMSG and hCG. Corresponding PA activity and PAI-1 activity/antigen levels in the FF were examined by fibrin overlay, reverse fibrin overlay, and Western blot, respectively. Although a considerable amount of tPA activity was pro-


duced and secreted by GCs from follicles 12–36 h before ovulation (Fig. 2, A and B), very little free tPA activity was measured in FF of follicles at 12–24 h after hCG treatment. Most of the tPA activity in the FF was found to be in complexes with PAI-1 12 h after hCG treatment (Fig. 5A, 12 h). As ovulation approached (24 h after hCG injection), the free tPA level was slightly increased, whereas PA activities bound in the PA-PAI-1 complexes also increased (Fig. 5A, 24 h), which is in agreement with our data in Figs. 2 and 4 that both tPA and PAI-1 levels had increased at this time point. Just before the onset of ovulation (Fig. 5A, 36 h after hCG injection), free tPA activities in the FF were dramatically elevated, whereas PA activities bound in PA-PAI-1 complexes became very low. Fluctuations in PAI-1 activity (Fig. 5B) and protein levels (Fig. 5C) were also evaluated in the FF of preovulatory follicles. A maximum level of PAI-1 was detected in FF 24 h after hCG treatment, which was 12 h earlier than the highest free tPA level in FF (Fig. 5A). However, just before ovulation (36 h after hCG treatment), the PAI-1 level decreased to an undetectable level (Fig. 5, B and C). Northern blot analysis of tPA mRNA content in GCs of adult monkey ovaries

FIG. 4. Gonadotropin regulation of PAI-1 secretion by monkey TICs during the periovulatory period. Prepubertal monkeys were treated with PMSG and/or hCG. The ovaries were removed at various times after gonadotropin treatment and TICs were prepared as described in Materials and Methods. TIC (5 ⫻ 105 cells/time point) were incubated at 37 C in 0.5 ml McCoy’s 5A medium for 24 h, and PAI-1 antigen levels in the conditioned media were measured by Western blot. PMSG: 12 d after PMSG treatment; 12 h, 24 h, 36 h, 3d: times after hCG treatment. For each time point of an experiment, cells from the ovaries of one female monkey were used. A, A representative photograph from three independent experiments. B, Average relative levels of tPA and uPA activities (mean ⫾ SD) of three experiments. Small letters (a, b, and d) indicate significant differences (P ⬍ 0.05).

At various time points after the hormone treatment, GCs were obtained by puncturing developed follicles of adult monkey ovaries. Total RNA from each group was prepared, fractionated by agarose gel electrophoresis and transferred onto nylon filters. The filters were hybridized with 32Plabeled monkey tPA riboprobe. The relative levels of tPA mRNA were calculated by densitometric scanning of autoradiographs and normalized against the corresponding GAPDH mRNA levels. As shown in Fig. 6, GC from PMSG treated (12 d) adult monkey ovaries contained very low levels of tPA mRNA. Treatment with hCG considerably induced tPA mRNA synthesis in the GCs in a time-dependent manner, reaching its maximum level 36 h after hCG injection.

FIG. 5. PA and PAI-1 levels in FF during the periovulatory period. Prepubertal monkeys were treated with PMSG and/or hCG. The ovaries were removed at various times after gonadotropin treatment. FF was collected from preovulatory follicles of prepubertal monkeys 12, 24, and 36 h after hCG injection, as described in Materials and Methods. PA (A) and PAI-1 (B) activities as well as PAI-1 antigen levels (C) were determined by fibrin overlay, reverse fibrin overlay, and Western blot analysis, respectively. For each time point of the experiment, FF from the ovaries of one female monkey was used. The result shown is a representative photograph from three independent experiments; 12, 24, and 36 h: time after hCG treatment.

1772


FIG. 6. Changes of tPA mRNA levels in granulosa cells of adult monkeys treated with PMSG and hCG. Adult monkeys were treated with PMSG for 12 d and followed by injection of hCG as described in Materials and Methods. Total RNA from GCs of each group (5 ⫻ 106 cells) was prepared by the Nonidet P-40 method and fractionated by agarose gel electrophoresis before being transferred onto nylon filters and hybridized with 32P-labeled antisense monkey tPA riboprobe. For each time point of one experiment, cells from two ovaries of one monkey were used. The relative amounts of tPA mRNA (mean ⫾ SD) were estimated by densitometric scanning of the autoradiographs and normalized against the corresponding amounts of GAPDH mRNA from three Northern blot analyses. Different letters indicate significant difference between the points (P ⬍ 0.05). PMSG: monkeys treated with PMSG for 12 d; PH12, PH36, and D3: 12 h, 36 h, and 3 d after hCG injection.

The quantity of tPA mRNA then decreased to a significantly lower level after ovulation (3 d after hCG treatment). In situ hybridization analysis of tPA and PAI-1 mRNAs in adult monkey follicles

To confirm the coordinated expression of tPA and PAI-1 in monkey ovaries during the periovulatory period, we also measured the mRNA levels of tPA and PAI-1 in adult monkey ovaries during the periovulatory period. The results were consistent with the changes in their mRNA levels measured by Northern blot. Specifically, low levels of tPA (Fig. 7A) and PAI-1 (Fig. 7E) mRNAs were expressed in the monkey follicles treated with only PMSG for 12 d. In the preovulatory follicles treated with PMSG and hCG, tPA mRNA expression start to increase at 24 h after hCG treatment (Fig. 7B) in the GCs and was further increased in GCs at 36 h after hCG injection (Fig. 7C). PAI-1 mRNA was elevated in follicles in the TIC 24 h after hCG treatment (Fig. 7F). However, in accordance with our results at the protein level, PAI-1 mRNA was very low in TICs just before ovulation (36 h after hCG injection, Fig. 7G). The mRNA levels of both tPA and PAI-1 decreased to undetectable levels in copora lutea at 5 d after hCG injection (Fig. 7, D and H). Discussion

Ovulation is a complex physiological process that is controlled by multiple factors including hormones, growth factors, and cytokines (1– 4). Over the last century, theories concerning elements that cause ovulation have been proposed (3). Data published over the last decade have suggested that proteolytic activities mediated by the PA system may play a role in the ovulatory process in rodents (1, 4, 6 –9). To evaluate the roles of PA and PAI-1 in ovulation of the primate, we used a PMSG/hCG-induced, synchronized ovu-


lation model in the rhesus monkey. We have demonstrated for the first time that the coordinated expression of tPA and its physiological inhibitor PAI-1 takes place during the ovulatory process of rhesus monkeys. In this study, we have shown that in monkey ovaries, GCs are the major source of PA production, whereas TICs are the major source of PAI-1 production. Expression of both tPA and PAI-1 was induced in monkey follicles by treatment with gonadotropins (PMSG and hCG), and maximum levels were reached before ovulation. However, the peak levels of tPA and PAI-1 appeared at different times before ovulation, with the peak of PAI-1 occurring about 12 h earlier than that of tPA. When tPA reached its highest level, the expression of PAI-1 had already decreased to its lowest level. Thus, our data indicate that tPA and PAI-1 expression is temporally coordinated during the ovulatory process of the monkey. Such coordinated expression of tPA and PAI-1 may generate high tPA activity in follicles just before ovulation, which may facilitate the breakdown of the follicular wall during ovulation. We also found that although monkey GCs can produce a considerable amount of uPA, uPA was not secreted from the GC cells before ovulation but was secreted by luteal cells after ovulation at the time when secreted tPA decreased to undetectable levels. Our results suggest that tPA produced by GCs is the major PA species taking part in the process of follicle rupture during ovulation in rhesus monkey ovaries. On the other hand, uPA is the major PA species that participates in the active tissue remodeling and angiogenesis processes during corpus luteum formation and development (16, 17). Little is known about the roles of the PA system in human ovaries. Human GCs collected from preovulatory follicles were reported to contain little or no tPA or uPA mRNA (23). Nevertheless, in the FF of human preovulatory follicles, low levels of tPA were detected (24). Moreover, relatively abundant amounts of PAI-1 mRNA were reported in human GCs or granulosa-luteal cells (23–25). The difference in the expression of tPA and PAI-1 in GCs and FF of preovulatory human follicles compared with the results we obtained from monkey ovaries may have several explanations. There might be species variations between humans and monkeys. However, we have also noticed that the expression of PA and PAI-1 during the periovulatory process in monkeys showed a temporal pattern that changed in a matter of hours. In our experiments, GC or FF samples obtained at different time points during the periovulatory period contained significantly different levels of PA and PAI-1. Therefore, it seems to us that what type of results can be obtained from human GCs and FF may also depend on the stage and condition of the clinical samples. The hypothesis that tPA and PAI-1 play a role in monkey ovulation is supported by previous studies in rodents. In the rat, GCs synthesize most of the follicular tPA activity (26), whereas the follicular wall (TICs) contributes most of the PAI-1 activity (27, 28). PAI-1 may therefore serve as a specific barrier to localize the tPA activity within the follicle (4, 9, 27, 28). As ovulation approaches, the level of PAI-1 in TICs and GCs dramatically decreases, whereas tPA activity in the follicle rises to its maximum level. The coordinated expression



FIG. 7. Localization of tPA and PAI-1 mRNAs in preovulatory monkey follicles. Frozen sections (10 –12 ␮m) from ovaries of adult female monkeys 12 d after PMSG treatment (A, E), 24 h (B, F), 36 h (C, G), or 5 d (D, H) after treatment with hCG were hybridized with digoxigenin-labeled monkey tPA (A–D) and PAI-1 (E–H) probes as described in Materials and Methods. Slides for comparison were prepared at the same time. Photographs were taken at original magnification ⫻10. Representative pictures from three individual experiments (n ⫽ one monkey per time point for each experiment) are shown. CL, Corpus luteum.

of tPA and PAI-1 may therefore lead to a short pulse of proteolytic activity that could play a role in rupture of the follicle (4, 9, 27, 28). However, an important challenge is to determine the roles of the PA system in primate ovulation, compared with the limited positive data from PA and plasminogen knockout mice (13, 14). It is well known that species differences exist in the expression of the PA system in ovaries. For example, both uPA and tPA have been detected in the mouse ovary (29 –31). In contrast to the rat, 70 – 80% of secreted PA activities by mouse GCs were from uPA, and both tPA and uPA were induced by gonadotropins and reached their maximum levels before ovulation (30, 31). In addition, no PAI-1 activity was detected in mouse GCs and FF, whereas the activity of

a plasmin inhibitor, ␣2-antiplasmin, was found in the FF (32). Using chicken and pig models, Politis et al. (33) and Tilly et al. (34) also demonstrated that tPA is the principal PA in the preovulatary follicles of these species. Despite the abovementioned results, we also examined the ovarian PA activities in other species, such as amphioxus, rabbit, cat, hamster, and giant panda. Ovaries of these species contained mainly tPA activities, which were regulated by gonadotropins (our unpublished data). Thus, we suggest that tPA may be the key PA type that plays roles in ovulation of various species. Studies of PA and plasminogen-deficient mouse strains have indicated that other families of proteases including the matrix metalloproteinases and their inhibitors may also be involved in follicle rupture during ovulation (14, 35–38).

1774 Endocrinology, April 2004, 145(4):1767–1775

Ovulation is also modulated by endogenously produced local factors that can regulate the expression and localization of PAs and matrix metalloproteinases (for papers and reviews, see Refs. 1–5, 9, 39 – 42). In addition, the gonadotropininduced ovulatory process in mammals involves gross physiological events that are similar to acute inflammatory reactions regulated by various genes in the ovary (43– 45). Thus, it seems to us that the next challenge is to identify how multiple paracrine and autocrine factors regulate other proteases and protease inhibitors during the periovulatory period in the primate.


17.

18. 19.

20. 21.

Acknowledgments The authors thank Dr. Ann Clark for proofreading the manuscript. Received October 3, 2003. Accepted December 22, 2003. Address all correspondence and requests for reprints to: Professor Yi-Xun Liu, State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100080, China. E-mail: [email protected]. Present address for Q.F.: Department of Obstetrics and Gynecology, Research Division, University of British Columbia, British Columbia Women’s Hospital and Health Center, 4490 Oak Street, Room 2H30, Vancouver, British Columbia, Canada V6H 3N1. This work was supported by the National Natural Science Foundation of China (39970284, 90208025, 30170452, 30370200); World Health Organization/Rockefeller Foundation; “CAS Chuangxin”(KSCX-2-SW201) and “973” (G1999055901) Programs; and the Swedish Medical Research Council (Research Grants K97-13X-09709-07A, K99-72X13144-01A).

22. 23.

24.

25.

26.

27.

28.

References 1. Tsafriri A, Reich R 1999 Molecular aspects of mammalian ovulation. Exp Clin Endocrinol Diabetes 107:1–11 2. Richards J-S, Russell D-L, Ochsner S, Espey L-L 2002 Ovulation: new dimensions and new regulators of the inflammatory-like response. Annu Rev Physiol 64:69 3. Niswender GD, Nett TM 1994 The corpus luteum and its control in infraprimate species. In: Knobil E, Neill JD, eds. Physiology of reproduction. 2nd ed. New York: Raven Press; 781– 816 4. Ny T, Wahlberg P, Brandstrom IJ 2002 Matrix remodeling in the ovary: regulation and functional role of the plasminogen activator and matrix metalloproteinase systems. Mol Cell Endocrinol 22:187:29 –38 5. Curry Jr TE, Osteen KG 2001 Cyclic changes in the matrix metalloproteinase system in the ovary and uterus. Biol Reprod 64:1285–1296 6. Beers WH, Strickland S, Reich E 1975 Ovarian plasminogen activator: relationship to ovulation and hormonal regulation. Cell 6:387–394 7. Strickland S, Beers WH 1976 Studies on the role of plasminogen activator in ovulation. In vitro response of granulosa cells to gonadotropins, cyclic nucleotides, and prostaglandins. J Biol Chem 251:5694 –5702 8. Reich R, Miskin R, Tsafriri A 1985 Follicular plasminogen activator: involvement in ovulation. Endocrinology 116:516 –521 9. Liu YX 1999 Regulation of the plasminogen activator system in the ovary. Biol Signals Recept 8:160 –177 10. Vassalli JD, Sappino AP, Belin D 1991 The plasminogen activator/plasmin system. J Clin Invest 88:1067–1072 11. Loskutoff DJ 1988 Type 1 plasminogen activator inhibitor and its potential influence on thrombolytic therapy. Semin Thromb Hemost 14:100 –109 12. Tsafriri A, Bicsak TA, Cajander SB, Ny T, Hsueh AJ 1989 Suppression of ovulation rate by antibodies to tissue-type plasminogen activator and ␣ 2antiplasmin. Endocrinology 124:415– 421 13. Leonardsson G, Peng XR, Liu K, Nordstrom L, Carmeliet P, Mulligan R, Collen D, Ny T 1995 Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. Proc Natl Acad Sci USA 92:12446 –12450 14. Ny A, Leonardsson G, Hagglund AC, Hagglof P, Ploplis VA, Carmeliet P, Ny T 1999 Ovulation in plasminogen-deficient mice. Endocrinology 140:5030 – 5035 15. Feng Q, Liu K, Hu ZY, Zou RJ, Yang SC, Liu YX 1993 The possible involvement of tissue type plasminogen activator in luteolysis of rhesus monkey. Human Reprod 8:1640 –1644 16. Liu K, Liu YX, Hu ZY, Zou YJ, Chen YJ, Mu XM, Ny T 1997 Temporal expression of urokinase type plasminogen activator, plasminogen activator

29.

30. 31.

32. 33.

34.

35.

36.

37.

38.

39.

40.

41.

inhibitor type-1 in rhesus monkey corpus luteum during the luteal maintenance and regression. Mol Cell Endocrinol 133:109 –116 Liu K, Feng Q, Gao HJ, Hu ZY, Zou YJ, Li YC, Liu YX 2003 Expression and regulation of plasminogen activators (PAs), plasminogen activator inhibitor type-1 (PAI-1) and steroidogenic acute regulatory protein (StAR) in the rhesus monkey corpus luteum. Endocrinology 144:3611–3617 Bavister BD, Boatman DE, Leibfried L, Loose M, Vernon MW 1983 Fertilization and cleavage of rhesus monkey oocytes in vitro. Biol Reprod 28:983–999 Liu YX, Hsueh AJW 1986 Synergism between granulosa and theca-interstitial cells in estrogen biosynthesis by gonadotropin-treated rat ovaries: studies on the two-cell, two gonadotropin hypothesis using steroid antisera. Biol Reprod 35:27–36 Granelli-Piperno A, Reich E 1987 A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 148:223–234 Liu K, Brandstrom A, Liu YX, Ny T, Selstam G 1996 Coordinated expression of tissue-type plasminogen activator and plasminogen activator inhibitor type I during corpus luteum formation and luteolysis in the adult pseudopregnant rat. Endocrinology 137:2126 –2132 Sokal RR, Rohlf FJ 1981 The principals and practice of statistics in biological research. In: Biometry. 2nd ed. New York: W. H. Freeman Co.; 232–279 Jones PB, Muse KN, Wilson EA, Curry Jr TE 1988 Expression of plasminogen activator (PA) and a PA inhibitor in human granulosa cells from preovulatory follicles. J Clin Endocrinol Metab 67: 857– 860 Jones PB, Vernon MW, Muse KN, Curry Jr TE 1989 Plasminogen activator and plasminogen activator inhibitor in human preovulatory follicular fluid. J Clin Endocrinol Metab 68:1039 –1045 Piquette GN, Crabtree ME, el-Danasouri I, Milki A, Polan ML 1993 Regulation of plasminogen activator inhibitor-1 and -2 messenger ribonucleic acid levels in human cumulus and granulosa-luteal cells. J Clin Endocrinol Metab 76:518 –523 Reich R, Miskin R, Tsafriri A 1986 Intrafollicular distribution of plasminogen activators and their hormonal regulation in vitro. Endocrinology 119:1588 – 1593 Liu YX, Peng XR, Ny T 1991 Tissue-specific and time-coordinated hormone regulation of plasminogen-activator-inhibitor type I and tissue-type plasminogen activator in the rat ovary during gonadotropin-induced ovulation. Eur J Biochem 195:549 –555 Peng XR, Hsueh AJ, Ny T 1993 Transient and cell-specific expression of tissue-type plasminogen activator and plasminogen-activator-inhibitor type 1 results in controlled and directed proteolysis during gonadotropin-induced ovulation. Eur J Biochem 214:147–156 Canipari R, O’Connell ML, Meyer G, Strickland S 1987 Mouse ovarian granulosa cells produce urokinase-type plasminogen activator, whereas the corresponding rat cells produce tissue-type plasminogen activator. J Cell Biol 105:977–981 Liu YX, Feng QA, Liu JC, Hu ZY 1989 Plasminogen activator activity in mouse ovaries during periovulatory period. Sheng Li Xue Bao 41:284 –290 Hagglund AC, Ny A, Liu K, Ny T 1996 Coordinated and cell-specific induction of both physiological plasminogen activators creates functionally redundant mechanisms for plasmin formation during ovulation. Endocrinology 137:5671– 5677 Liu YX, Feng Q, Hu ZY 1992 Plasminogen activator inhibitor in mouse ovaries during periovulatory periods. Dev Reprod Biol 1:2– 8 Politis I, Wang L, Turner JD, Tsang BK 1990 Changes in tissue-type plasminogen activator-like and plasminogen activator inhibitor activities in granulose and theca layers during ovarian follicle development in the domestic hen. Biol Reprod 40:747–757 Tilly JL, Kowalski KI, Li Z, Levorde JM, Johnson, AL 1992 Plasminogen activator activity and thymidine incorporation avian granulose cells during follicular development and the periovulatory period. Biol Reprod 46:195–200 Reich R, Daphna-Iken D, Chun S-Y, Popliker M, Slager R, Adelmann-Grill B-C, Tsafriri A 1991 Preovulatory changes in ovarian expression of collagenases and tissue metalloproteinase inhibitor messenger ribonucleic acid: role of eicosanoids. Endocrinology 129:1869 –1875 Curry Jr T-E, Mann S-S, Huang M-H, Keeble S-C 1992 Gelatinase and proteoglycanase activity during the periovulatory period in the rat. Biol Reprod 46:256 –264 Tadakuma H, Okamura H, Kitaoka M, Iyama K, Usuku G 1993 Association of immunolocalization of matrix metalloproteinase 1 with ovulation in hCGtreated rabbit ovary. J Reprod Fertil 98:503–508 Chaffin C-L, Stouffer R-L 1999 Expression of matrix metalloproteinases and their tissue inhibitor messenger ribonucleic acids in macaque periovulatory granulosa cells: time course and steroid regulation. Biol Reprod 61:14 –21 Espey L-L, Ujioka T, Okamura H, Richards J-S 2003 Metallothionein-1 messenger RNA transcription in steroid-secreting cells of the rat ovary during the periovulatory period. Biol Reprod 68:1895–1902 Robker R-L, Russell D-L, Espey L-L, Lydon J-P, O’Malley B-W, Richards J-S 2000 Progesterone-regulated genes in the ovulation process: ADAMTS-1 and cathepsin L proteases. Proc Natl Acad Sci USA 97:4689 – 4694 Galway A-B, Oikawa M, Ny T, Hsueh A-J 1989 Epidermal growth factor


stimulates tissue plasminogen activator activity and messenger ribonucleic acid levels in cultured rat granulosa cells: mediation by pathways independent of protein kinases-A and -C. Endocrinology 125:126 –135 42. Jia X-C, Ny T, Hsueh A-J 1990 Synergistic effect of glucocorticoids and androgens on the hormonal induction of tissue plasminogen activator activity and messenger ribonucleic acid levels in granulosa cells. Mol Cell Endocrinol 68:143–151


43. Espey L-L 1980 Ovulation as an inflammatory reaction—a hypothesis. Biol Reprod 22:73–106 44. Espey L-L 1994 Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biol Reprod 50:233–238 45. Robker R-L, Russell D-L, Yoshioka S, Sharma S-C, Lydon J-P, O’Malley B-W, Espey L-L, Richards J-S 2000 Ovulation: a multigene, multistep process. Steroids 65:559 –570

Endocrinology is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.